RenovoRx, Inc. (NASDAQ: RNXT) announced it has regained compliance with Nasdaq’s minimum bid price requirement, citing a closing bid price of at least $1.00 per share for 10 consecutive business days from August 6 through August 19, 2026.
The company received notification from Nasdaq Listing Qualifications Staff on August 20, 2026, confirming compliance with Nasdaq Listing Rule 5550(a)(2). The deficiency notice had been issued on December 31, 2025, following a prior failure to meet the minimum bid price threshold.
RenovoRx also reported second-quarter revenue of $909,000 for 2026 and approximately $1.1 million in RenovoCath sales for the full year 2025. The company’s RenovoCath device, a drug-delivery system cleared by the FDA for temporary vessel occlusion, remains a key focus, though it is not yet approved for commercial sale as a drug-device combination product.
The company’s Phase III TIGeR-PaC trial, evaluating RenovoCath with gemcitabine for pancreatic cancer, completed enrollment in August 2026. Topline data is expected in the second half of 2027, with full trial completion anticipated in the first half of 2027. RenovoCath with gemcitabine holds Orphan Drug Designation for pancreatic and bile duct cancers, which would grant seven years of market exclusivity upon FDA approval.
The trading symbol RNXT remains listed on The Nasdaq Capital Market, and the compliance notification does not impact the company’s common stock trading.
